Discrepancy in p16 expression in patients with HPV-associated head and neck squamous cell carcinoma in Thailand : clinical characteristics and survival outcomes
BACKGROUND: Lower prevalence HPV infection has been previously reported in Thai population when compared with Western countries. p16 expression indicates HPV-associated oropharyngeal squamous cell carcinoma (OPSCC), but not non-OPSCC. We therefore evaluated the characteristic and association of p16 and HPV in Thai patients with HNSCC.
METHODS: We used immunohistochemistry and qPCR, respectively, to detect p16 and HPV DNA in archrival formalin-fixed paraffin-embedded HNSCC tissues. Patient characteristics and survival were analyzed.
RESULTS: p16 expression was detected in tumors of 72 of 662 (10.9%) patients with HNSCC and was significantly associated with higher-grade histology, advanced nodal stage, and oropharynx. p16 was expressed in 28 and 6.5% of patients with OPSCC or non-OPSCC, respectively, and HPV DNA was detected in 15.6 and 1% of patients, respectively. Using p16 as a surrogate for HPV status, sensitivities were 80 and 25% in OPSCC and non-OPSCC, respectively. Positive and negative predictive rates of OPSCC were 38 and 95%. Discordance rates between HPV and p16 were 23 and 7% in OPSCC and non-OPSCC, respectively. Overall survival (OS) were significantly longer in both p16-positive OPSCC (p = 0.049), and non-OPSCC (p = 0.003).
CONCLUSIONS: Low prevalence of p16 and HPV associated OPSCC and non-OPSCC were confirmed in Thai patients. High discordance and low positive predictive rates of p16 were observed in HPV-associated OPSCC. p16 was a significant prognostic factor for OS for patients with OPSCC or non-OPSCC. Therefore, HPV testing should be performed to assess the association of HPV with HNSCC regardless of p16 expression.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
BMC cancer - 21(2021), 1 vom: 06. Mai, Seite 504 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arsa, Lalida [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CDKN2A protein, human |
|---|
| Anmerkungen: |
Date Completed 18.10.2021 Date Revised 18.10.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12885-021-08213-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325097577 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325097577 | ||
| 003 | DE-627 | ||
| 005 | 20231225191720.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12885-021-08213-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1083.xml |
| 035 | |a (DE-627)NLM325097577 | ||
| 035 | |a (NLM)33957888 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arsa, Lalida |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Discrepancy in p16 expression in patients with HPV-associated head and neck squamous cell carcinoma in Thailand |b clinical characteristics and survival outcomes |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.10.2021 | ||
| 500 | |a Date Revised 18.10.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Lower prevalence HPV infection has been previously reported in Thai population when compared with Western countries. p16 expression indicates HPV-associated oropharyngeal squamous cell carcinoma (OPSCC), but not non-OPSCC. We therefore evaluated the characteristic and association of p16 and HPV in Thai patients with HNSCC | ||
| 520 | |a METHODS: We used immunohistochemistry and qPCR, respectively, to detect p16 and HPV DNA in archrival formalin-fixed paraffin-embedded HNSCC tissues. Patient characteristics and survival were analyzed | ||
| 520 | |a RESULTS: p16 expression was detected in tumors of 72 of 662 (10.9%) patients with HNSCC and was significantly associated with higher-grade histology, advanced nodal stage, and oropharynx. p16 was expressed in 28 and 6.5% of patients with OPSCC or non-OPSCC, respectively, and HPV DNA was detected in 15.6 and 1% of patients, respectively. Using p16 as a surrogate for HPV status, sensitivities were 80 and 25% in OPSCC and non-OPSCC, respectively. Positive and negative predictive rates of OPSCC were 38 and 95%. Discordance rates between HPV and p16 were 23 and 7% in OPSCC and non-OPSCC, respectively. Overall survival (OS) were significantly longer in both p16-positive OPSCC (p = 0.049), and non-OPSCC (p = 0.003) | ||
| 520 | |a CONCLUSIONS: Low prevalence of p16 and HPV associated OPSCC and non-OPSCC were confirmed in Thai patients. High discordance and low positive predictive rates of p16 were observed in HPV-associated OPSCC. p16 was a significant prognostic factor for OS for patients with OPSCC or non-OPSCC. Therefore, HPV testing should be performed to assess the association of HPV with HNSCC regardless of p16 expression | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HPV | |
| 650 | 4 | |a Head and neck squamous cell carcinoma | |
| 650 | 4 | |a OPSCC | |
| 650 | 4 | |a Oropharyngeal squamous cell carcinoma | |
| 650 | 4 | |a p16 | |
| 650 | 7 | |a CDKN2A protein, human |2 NLM | |
| 650 | 7 | |a Cyclin-Dependent Kinase Inhibitor p16 |2 NLM | |
| 650 | 7 | |a DNA, Viral |2 NLM | |
| 700 | 1 | |a Siripoon, Teerada |e verfasserin |4 aut | |
| 700 | 1 | |a Trachu, Narumol |e verfasserin |4 aut | |
| 700 | 1 | |a Foyhirun, Sasithorn |e verfasserin |4 aut | |
| 700 | 1 | |a Pangpunyakulchai, Duangjai |e verfasserin |4 aut | |
| 700 | 1 | |a Sanpapant, Suda |e verfasserin |4 aut | |
| 700 | 1 | |a Jinawath, Natini |e verfasserin |4 aut | |
| 700 | 1 | |a Pattaranutaporn, Poompis |e verfasserin |4 aut | |
| 700 | 1 | |a Jinawath, Artit |e verfasserin |4 aut | |
| 700 | 1 | |a Ngamphaiboon, Nuttapong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cancer |d 2001 |g 21(2021), 1 vom: 06. Mai, Seite 504 |w (DE-627)NLM111431948 |x 1471-2407 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:1 |g day:06 |g month:05 |g pages:504 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12885-021-08213-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 1 |b 06 |c 05 |h 504 | ||